Breast cancer detection kit Rucsen®

for genestissueclinical

Breast cancer is the most common cancer in women and one of the leading causes of cancer-related deaths among women. The 21-gene test for breast cancer is a quantitative detection of mRNA expression levels of 21 genes associated with breast cancer. Specific algorithms are used to convert gene expression levels into a recurrence score (RS), and the score is used to determine whether breast cancer patients need adjuvant chemotherapy. The results of this test can provide information on prognosis, recurrence, and guide treatment. In the updated NCCN Clinical Practice Guidelines for Breast Cancer (Version 3, 2018), which references the TAILORx study and previous research, the 21-gene test is now strongly considered for invasive breast cancer. The RS grading system can identify patients with a low risk of recurrence who can be spared from chemotherapy and avoid overtreatment. FEATURES & ADVANTAGES 1. Simple and Efficient: Using high-efficiency reverse transcriptase, the reverse transcription can be completed in 30 minutes. 2. Accurate and Reliable: Based on real-time fluorescence quantitative PCR platform, using Taqman probe method, high specificity and sensitivity. 3. Professional and Convenient: Professional calculation formula, directly calculate the RS value, simple and convenient. DETECTION PROCESS 1. Nucleic Acid Extraction 3. Amplification 4. Data Analysis DETECTION SIGNIFICANCE Patients with ER+ and HER2- invasive breast cancer can evaluate the risk of recurrence and the benefit of chemotherapy through 21 gene detection,